Phuong Khanh Morrow - 13 Oct 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CRSP
Reported as of: 13 Oct 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Oct 2023, 17:52:27 UTC
Prior SEC filing: 25 May 2023
Next SEC filing: 07 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Phuong Khanh Morrow filed Form 4 for CRISPR Therapeutics AG (CRSP) on 17 Oct 2023.

Key facts

This page summarizes Phuong Khanh Morrow's Form 4 filing for CRISPR Therapeutics AG (CRSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Oct 2023, 17:52.

Change

Previous filing in this sequence was filed on 25 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,667
Change %
Price: $0.000000
Shares after: 16,667
Date: 13 Oct 2023
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 16,667
Exercise price: $44.31
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.